NO941310D0 - Sammensetning og fremgangsmåte for behandling av hepatitt C - Google Patents

Sammensetning og fremgangsmåte for behandling av hepatitt C

Info

Publication number
NO941310D0
NO941310D0 NO941310A NO941310A NO941310D0 NO 941310 D0 NO941310 D0 NO 941310D0 NO 941310 A NO941310 A NO 941310A NO 941310 A NO941310 A NO 941310A NO 941310 D0 NO941310 D0 NO 941310D0
Authority
NO
Norway
Prior art keywords
thymosin
hepatitis
treatment
composition
immune system
Prior art date
Application number
NO941310A
Other languages
English (en)
Norwegian (no)
Other versions
NO941310L (no
Inventor
Paul Chretian
Milton Mutchnick
Kenneth E Sherman
Original Assignee
Alpha 1 Biomedicals Inc
Milton Mutchnick
Kenneth E Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Milton Mutchnick, Kenneth E Sherman filed Critical Alpha 1 Biomedicals Inc
Publication of NO941310L publication Critical patent/NO941310L/no
Publication of NO941310D0 publication Critical patent/NO941310D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
NO941310A 1991-09-13 1994-04-12 Sammensetning og fremgangsmåte for behandling av hepatitt C NO941310D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (2)

Publication Number Publication Date
NO941310L NO941310L (no) 1994-04-12
NO941310D0 true NO941310D0 (no) 1994-04-12

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941310A NO941310D0 (no) 1991-09-13 1994-04-12 Sammensetning og fremgangsmåte for behandling av hepatitt C

Country Status (23)

Country Link
US (3) US6001799A (cs)
EP (1) EP0603305B1 (cs)
JP (1) JP3228512B2 (cs)
KR (1) KR100254082B1 (cs)
AT (1) ATE152914T1 (cs)
AU (1) AU667327B2 (cs)
CA (1) CA2119006C (cs)
CZ (1) CZ286827B6 (cs)
DE (1) DE69219782T2 (cs)
DK (1) DK0603305T3 (cs)
ES (1) ES2103966T3 (cs)
FI (1) FI107879B (cs)
GR (1) GR3024025T3 (cs)
HK (1) HK1021687A1 (cs)
HU (1) HU221006B1 (cs)
MX (1) MX9205240A (cs)
NO (1) NO941310D0 (cs)
RO (1) RO111991B1 (cs)
RU (1) RU2104010C1 (cs)
SG (1) SG64897A1 (cs)
TW (1) TW224053B (cs)
WO (1) WO1993005806A1 (cs)
ZA (1) ZA926964B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
CA2175337C (en) * 1993-11-05 2000-06-20 Paul B. Chretien Method and composition for treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
KR100394382B1 (ko) * 1996-02-28 2004-02-05 유니하트 코포레이션 천연사람α-인터페론으로구성된약학조성물
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
AU2001283536B2 (en) * 2000-08-07 2005-09-01 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin, interferon and ribavirin
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
PL371683A1 (en) * 2001-10-05 2005-06-27 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
EP1448223B1 (en) * 2001-10-26 2008-01-02 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
NZ534811A (en) * 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
AU2004226403B2 (en) * 2003-03-28 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
EP1633766B1 (en) 2003-05-30 2019-03-06 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
ES2351603T3 (es) 2003-07-25 2011-02-08 Idenix Pharmaceuticals, Inc. Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c.
WO2005021007A1 (en) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention and treatment of viral hepatitis c
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
BRPI0711136A2 (pt) * 2006-05-02 2011-08-30 Sigma Tau Ind Farmaceuti uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (cs) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
US6001799A (en) 1999-12-14
JP3228512B2 (ja) 2001-11-12
DE69219782T2 (de) 1997-10-09
ES2103966T3 (es) 1997-10-01
ATE152914T1 (de) 1997-05-15
CZ286827B6 (cs) 2000-07-12
WO1993005806A1 (en) 1993-04-01
JPH06510998A (ja) 1994-12-08
HK1021687A1 (en) 2000-06-23
US20070218033A1 (en) 2007-09-20
RU2104010C1 (ru) 1998-02-10
DK0603305T3 (da) 1997-09-01
KR100254082B1 (ko) 2000-09-01
HU9400758D0 (en) 1994-06-28
RO111991B1 (ro) 1997-04-30
SG64897A1 (en) 1999-05-25
NO941310L (no) 1994-04-12
FI941133A0 (fi) 1994-03-10
US5849696A (en) 1998-12-15
EP0603305A1 (en) 1994-06-29
ZA926964B (en) 1993-04-26
FI941133L (fi) 1994-03-10
GR3024025T3 (en) 1997-10-31
FI107879B (fi) 2001-10-31
CZ55194A3 (en) 1994-10-19
AU2644792A (en) 1993-04-27
EP0603305B1 (en) 1997-05-14
TW224053B (cs) 1994-05-21
DE69219782D1 (de) 1997-06-19
HU221006B1 (hu) 2002-07-29
AU667327B2 (en) 1996-03-21
HUT75166A (en) 1997-04-28
CA2119006A1 (en) 1993-04-01
RU94022480A (ru) 1996-07-20
MX9205240A (es) 1993-07-01
CA2119006C (en) 2005-08-23

Similar Documents

Publication Publication Date Title
NO941310D0 (no) Sammensetning og fremgangsmåte for behandling av hepatitt C
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
AU4205789A (en) Method and composition for the treatment and prevention of viral infections
NO951340D0 (no) Fremgangsmåte til å behandle lungesykdom med uridintrifosfater
FR2709966B1 (fr) Vaccin pour la prévention du syndrome respiratoire et de la reproduction du porc.
FI943028L (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
EP0325129A3 (en) Disubstituted pyridines
EP0627930A4 (en) COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
DK0583281T3 (da) Modgift - immunsera
FI941705L (fi) Menetelmä viruspatogeenien läpipääsyn estämiseksi
ATE76579T1 (de) Interferon-zusammensetzungen.
NO910219L (no) Behandling av tre og trebaserte materialer.
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
DE3884652D1 (de) Gate-Ausschaltthyristor und Verfahren zu dessen Herstellung.
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
NO933628D0 (no) Fremgangsmaate og blanding for behandling av herpes-infeksjoner
MY110041A (en) Composition and method of treating hepatitis c
DK0497356T3 (da) Sammensætninger og fremgangsmåde til tumorer i blødt væv
NO961775D0 (no) Fremgangsmåte og sammensetning for behandling av pasienter med dekompensert leversykdom
ZA897105B (en) Method and composition for the treatment of viral infections
NO910474D0 (no) Oppvarmet transportoer og metode for desinfisering av forurenset sykehus-avfall med liten stoerrelse.
GB9112552D0 (en) Method and composition for the treatment of cancer
SE9101471D0 (sv) Foerfarande foer tillverkning av byggelement och byggelement tillverkat enligt foerfarandet